NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

青光眼治療市場:2020-2026

Glaucoma treatment Market 2020-2026

出版商 Orion Market Research Pvt Ltd 商品編碼 1008110
出版日期 內容資訊 英文
商品交期: 2-3個工作天內
價格
青光眼治療市場:2020-2026 Glaucoma treatment Market 2020-2026
出版日期: 2021年05月04日內容資訊: 英文
簡介

在預測期內(2021-2027 年),全球青光眼治療市場預計將以 5.2% 的顯著複合年增長率增長。青光眼是主要的眼部疾病之一,可損害視神經並導致視力喪失和失明。它被稱為安靜的視力竊賊,並且在您發現視力異常之前是無痛的。青光眼通常是由人的眼內壓升高引起的。它主要發生在 40 歲以上的人群中,但在世界範圍內也觀察到先天性青光眼。老年人口的增加是導致青光眼發病率增加的關鍵因素之一。青光眼的發病率和患病率在世界範圍內以顯著的速度增加。根據世界衛生組織 (WHO) 的數據,到 2020 年,全球將有約 22 億人遭受某種形式的視力損害,其中 80.0% 是可以避免的。

青光眼最常見的治療方法是滴眼液,很少使用藥片。然而,手術治療的進步促進了眼科雷射光在青光眼治療中的應用。用於治療青光眼的雷射光手術包括選擇性雷射光小梁成形術(SLT)、氬雷射光小梁成形術(ALT)、雷射光周邊虹膜切開術(LPI)和雷射光睫狀體光凝術等多種類型。除此之外,持續的藥物創新和糖尿病患者人數的增加提供了巨大的增長機會。阻礙市場增長的因素包括不同地區對該疾病及其治療缺乏認識,以及青光眼手術後出現的術後併發症。對青光眼的認識不斷提高和技術進步也為青光眼治療市場創造了機會。除此之外,除了視覺障礙之外,沒有疼痛和症狀也不被視為市場挑戰。

本報告調查了青光眼治療市場,並按藥物類別、疾病適應症、分銷渠道、地區和進入市場的公司概況介紹了市場概況以及趨勢。

目錄

第 1 章報告概述

第 2 章市場概覽和洞察

  • 調查範圍
  • 管道分析:全球青光眼治療市場
  • 分析師洞察和當前市場趨勢

第 3 章競爭形勢

  • 主要公司分析
    • 概述
    • 財務分析
    • SWOT 分析
    • 近期發展
  • 重要的戰略分析

第 4 章市場決定因素

  • 動機
  • 抑制因素
  • 市場機會

第 5 章市場細分

  • 全球青光眼治療市場,按藥物類別
    • 前列腺素類似物
    • 阿爾法激動劑
    • 膽鹼能
    • Beta 攔截器
    • 碳酸酐□抑制劑
  • 全球青光眼治療市場,按疾病適應症
    • 閉角型青光眼 (CAG)
    • 開角型青光眼 (OAG)
    • 繼發性青光眼
    • 先天性青光眼
  • 按分銷渠道劃分的全球青光眼治療市場
    • 醫院藥房
    • 零售藥店
    • 網上藥店

第 6 章區域分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 意大利
    • 西班牙
    • 法國
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他
  • 其他領域

第 7 章公司簡介

  • Aerie Pharmaceuticals, Inc.
  • Akorn, Inc.
  • Allergan Plc
  • Bausch & Lomb Pvt. Ltd.
  • Bayer AG
  • Carl Zeiss AG
  • F. Hoffmann-La Roche, Ltd.
  • HOYA Corp.
  • InotekCorp.
  • Ivantis, Inc.
  • Johnson & Johnson Vision Care, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Santen Pharmaceuticals Co., Ltd.
  • Teva Pharmaceuticals Industries, Ltd.
  • Topcon Corp.
  • Valeant Pharmaceuticals International, Inc.
目錄
Product Code: OMR2023403

Global Glaucoma Treatment Market Size, Share & Trends Analysis Report By Disease Indication (Closed Angle Glaucoma (CAG), Open Angle Glaucoma (OAG), Secondary Glaucoma, and Congenital Glaucoma), By Distribution Channel (Hospitals PHARMACY, RETAIL Pharmacy, and Online Pharmacy), By Drug Class (Prostaglandin Analogues, Alpha Agonist, Cholinergic, Beta Blockers, and Carbonic Anhydrase Inhibitors), Forecast Period 2021-2027

The global glaucoma treatment market is anticipated to grow at a considerable CAGR of 5.2% during the forecast period (2021-2027). Glaucoma is one of the major eye disorders which causes damage to the optic nerve and can cause to result in vision loss and blindness. It is referred to as a silent thief of sight, it shows no pain observed until noticeable vision occurs. Glaucoma is generally observed due to raised intraocular tension in people. It mostly occurs in people over the age of 40, however, congenital glaucoma is also observed across the globe. The growing geriatric population is one of the key factors responsible for the growing incidence of glaucoma. The incidence and prevalence rate of glaucoma disease is growing at a significant rate across the globe. According to the World Health Organization (WHO), in 2020, around 2.2 billion people from across the globe had been suffering from one or the other kind of visual impairment and 80.0% of these were considered avoidable.

The most common treatments for glaucoma are eye drops and, rarely, pills. However, advancement in surgical treatment has boosted the growth of ophthalmic laser application in the treatment of glaucoma. There are various types of laser surgeries that are used for treating glaucoma such as Selective Laser Trabeculoplasty (SLT), Argon Laser Trabeculoplasty (ALT), Laser Peripheral Iridotomy (LPI), and Laser Cyclophotocoagulation among others. Apart from it, the continuous innovations in the drugs and rising number of patients with diabetes have resulted in significant growth opportunities. Although some factors hinder the growth of the market include a lack of awareness about the disease and its treatment in various regions, and postoperative complications resulting after glaucoma surgery. Rising awareness initiatives about glaucoma and technological advancements are also creating opportunities for the glaucoma treatment market. Besides this, no pain and lack of symptoms other than noticeable vision are considered as the challenge for the market.

The Impact of COVID-19 on The Global Glaucoma Treatment Market

The global glaucoma treatment market is expected to hardly hit by the COVID-19 pandemic. Since December 2019, the COVID-19 pandemic has impacted the market as the number of elective surgeries has been reduced due to the imposing of the lockdown across the globe, especially in China, India, and other Asian economies. The burden on pharmaceutical facilities to develop early diagnosis and treatment for COVID-19 has impacted the business of other pharmaceuticals. Further, from the demand side, the economies facing lockdown have witnessed a very low rate of elective treatment.

Segmental Outlook

The global glaucoma treatment market is segmented based on disease indication, drug class, and distribution channel. Based on the disease indication, the market is segmented into closed-angle glaucoma (CAG), open angle glaucoma (OAG), secondary glaucoma, and congenital glaucoma. Open angle glaucoma (OAG) and closed angle glaucoma (CAG) are the most common types of glaucoma. According to the International Council of Ophthalmology report, open angle and closed angle glaucoma individually account for about half of all glaucoma cases. In addition, they are responsible for the major cause of irreversible vision across the globe. Therefore, open angle glaucoma and angle-closure glaucoma segments are expected to have a significant share of the glaucoma treatment market. Besides, based on the distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. Apart from it, based on the drug class, the market is segmented into prostaglandin analogues, alpha agonist, cholinergic, beta blockers, and carbonic anhydrase inhibitors.

Global Glaucoma Treatment Market Share by Disease Indication, 2020 (%)

Source: OMR Global

Open Angle Glaucoma holds a significant share in the Market

The open angle glaucoma held the major share in 2020 and is also anticipated to grow during the forecast period. Open angle glaucoma is the common form of the disease in which the drainage angle formed by the cornea and iris is open, although the trabecular meshwork is partially closed. This disease happens slowly with no symptoms and damages the optic nerve. The factors such as the high prevalence of disorder as compared to other types of glaucoma are fostering the glaucoma treatment market globally. Besides, various glaucoma therapeutic drugs available to treat open angle glaucoma are assisting the segment to lead. For instance. In November 2017, Bausch & Lomb Inc., has announced the launch of the VYZULTA solution which assists in the reduction of IOP in patients with open-angle glaucoma and ocular hypertension. And the company has also introduced LUMIFY an over-the-counter eye drop for ocular redness in the eyes.

Regional Outlooks

The global glaucoma treatment market is further segmented based on geography including North America, Europe, Asia-Pacific, and the Rest of the World. North America holds a dominant position in the global glaucoma treatment market, followed by Europe. The growth is mainly due to the high prevalence of glaucoma, and economic stability which results in high healthcare expenditure. Moreover, the high number of research grants by some research agencies for innovation and growth in the treatment area is also fueling the regional market growth. For instance, the Glaucoma Research Foundation is working on investing $40,000 each for the R&D and new product innovation in the US. The primary focus of this investment is to explore new therapies and cures, thereby opening new opportunities in the field of cyclodiode laser and cyclophotocoagulation industry. Besides, Europe has a good scope of the market due to its capability of strong reimbursement policies and high presence of a patient pool.

Global Glaucoma Treatment Market Growth, by Region 2021-2027

Source: OMR Global

Asia-Pacific is Projected to Have Considerable Share in the Global Glaucoma Treatment market

Asia-Pacific is anticipated to hold a considerable market share in the global glaucoma treatment market. The factors that are assisting the region to grow at a faster rate include the increasing geriatric population in countries such as China and Japan. As per the World Bank, in 2019, around 28% of the Japanese population is more than 65 years. And around 11.47% of the China population is over 65years. The elderly are at a greater risk of developing glaucoma, but people of all ages group may be affected. The increasing awareness, rising healthcare expenditure, and screening also propelling the growth. For instance, as per the World Health Organization (WHO), in 2018, around 6.8% of GDP was the healthcare expenditure in the Asia-Pacific. Thus, the huge population base and rapid development in the healthcare sector are assisting the companies to develop their market in the Asia-Pacific region.

Market Players Outlook

The key players of the glaucoma treatment market Aeries Pharmaceuticals, Inc., Bausch & Lomb Inc., Inotek Pharmaceuticals, Novartis AG, Merck & Co., Pfizer Inc., Teva Pharmaceuticals Industries, Hoya Corp., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, geographical expansion, collaborations, and new product launches, to stay competitive in the market. For instance, in November 2019, Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company involved in the treatment of the patient with open angle glaucoma, retinal disease, and other diseases of the eye, has announced that it has acquired Avizorex Pharma, S.L. (AVX), a company for the treatment of dry eye disease. This acquisition was done for $10 million and has expanded the drug portfolio for the company.

The Report Covers

Market value data analysis of 2020 and forecast to 2027.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global glaucoma treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Opportunity Outlook
  • COVID-19 Impact Analysis
  • Recovery Scenarios
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. ByRegion

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Pipeline Analysis:Global Glaucoma Treatment Market
  • 2.3. Analyst Insight & Current Market Trends
    • 2.3.1. Key Findings
    • 2.3.2. Recommendations
    • 2.3.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Key Strategy Analysis

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Glaucoma Treatment Marketby Drug Class
    • 5.1.1. Prostaglandin Analogues
    • 5.1.2. Alpha Agonist
    • 5.1.3. Cholinergic
    • 5.1.4. Beta-Blockers
    • 5.1.5. Carbonic Anhydrase Inhibitors
  • 5.2. Global Glaucoma Treatment Marketby Disease Indication
    • 5.2.1. Closed Angle Glaucoma (CAG)
    • 5.2.2. Open Angle Glaucoma (OAG)
    • 5.2.3. Secondary Glaucoma
    • 5.2.4. Congenital Glaucoma
  • 5.3. Global Glaucoma Treatment Market by Distribution Channel
    • 5.3.1. Hospitals Pharmacy
    • 5.3.2. Retail Pharmacy
    • 5.3.3. Online Pharmacy

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. South Korea
    • 6.3.5. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Aerie Pharmaceuticals, Inc.
  • 7.2. Akorn, Inc.
  • 7.3. Allergan Plc
  • 7.4. Bausch & Lomb Pvt. Ltd.
  • 7.5. Bayer AG
  • 7.6. Carl Zeiss AG
  • 7.7. F. Hoffmann-La Roche, Ltd.
  • 7.8. HOYA Corp.
  • 7.9. InotekCorp.
  • 7.10. Ivantis, Inc.
  • 7.11. Johnson & Johnson Vision Care, Inc.
  • 7.12. Merck & Co., Inc.
  • 7.13. Novartis AG
  • 7.14. Pfizer, Inc.
  • 7.15. Regeneron Pharmaceuticals, Inc.
  • 7.16. Sanofi S.A.
  • 7.17. Santen Pharmaceuticals Co., Ltd.
  • 7.18. Teva Pharmaceuticals Industries, Ltd.
  • 7.19. Topcon Corp.
  • 7.20. Valeant Pharmaceuticals International, Inc.

LIST OF TABLES

  • 1. GLOBAL GLAUCOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY DISEASE INDICATION, 2020-2027 ($ MILLION)
  • 2. GLOBAL CLOSED ANGLE GLAUCOMA (CAG) MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 3. GLOBAL OPEN ANGLE GLAUCOMA (OAG) MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 4. GLOBAL SECONDARY GLAUCOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 5. GLOBAL CONGENITAL GLAUCOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 6. GLOBAL GLAUCOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
  • 7. GLOBAL HOSPITALS PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 8. GLOBAL RETAIL PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 9. GLOBAL ONLINE PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 10. GLOBAL GLAUCOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2020-2027 ($ MILLION)
  • 11. GLOBAL PROSTAGLANDIN ANALOGUES DRUG FOR GLAUCOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 12. GLOBAL ALPHA AGONIST FOR GLAUCOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 13. GLOBAL CHOLINERGIC FOR GLAUCOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 14. GLOBAL BETA BLOCKERS FOR GLAUCOMA TREATMENTRESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)

15. GLOBAL CARBONIC ANHYDRASE INHIBITORS FOR GLAUCOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION

  • 16. NORTH AMERICAN GLAUCOMA TREATMENT MARKETRESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 17. NORTH AMERICAN GLAUCOMA TREATMENT MARKETRESEARCH AND ANALYSIS BY DISEASE INDICATION,2020-2027 ($ MILLION)
  • 18. NORTH AMERICAN GLAUCOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
  • 19. NORTH AMERICAN GLAUCOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2020-2027 ($ MILLION)
  • 20. EUROPEAN GLAUCOMA TREATMENT MARKETRESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 21. EUROPEAN GLAUCOMA TREATMENT MARKETRESEARCH AND ANALYSIS BY DISEASE INDICATION, 2020-2027 ($ MILLION)
  • 22. EUROPEAN GLAUCOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
  • 23. EUROPEAN GLAUCOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2020-2027 ($ MILLION)
  • 24. ASIA-PACIFIC GLAUCOMA TREATMENT MARKETRESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 25. ASIA-PACIFIC GLAUCOMA TREATMENT MARKETRESEARCH AND ANALYSIS BY DISEASE INDICATION,2020-2027 ($ MILLION)
  • 26. ASIA-PACIFIC GLAUCOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
  • 27. ASIA-PACIFIC GLAUCOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2020-2027 ($ MILLION)
  • 28. REST OF THE WORLD GLAUCOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 29. REST OF THE WORLD GLAUCOMA TREATMENT MARKETRESEARCH AND ANALYSIS BY DISEASE INDICATION, 2020-2027 ($ MILLION)
  • 30. REST OF THE WORLD GLAUCOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
  • 31. REST OF THE WORLD GLAUCOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2020-2027 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL GLAUCOMA TREATMENT MARKET SHARE BY DISEASE INDICATION, 2020 VS 2027 (%)
  • 2. GLOBAL GLAUCOMA TREATMENT MARKET SHARE BY DISTRIBUTION CHANNEL, 2020 VS 2027 (%)
  • 3. GLOBAL GLAUCOMA TREATMENT MARKET SHARE BY DRUG CLASS, 2020 VS 2027 (%)
  • 4. GLOBAL GLAUCOMA TREATMENT MARKETSHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 5. GLOBAL CLOSED ANGLE GLAUCOMA (CAG) MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 6. GLOBALOPEN ANGLE GLAUCOMA (OAG) MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 7. GLOBAL SECONDARY GLAUCOMA MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 8. GLOBAL CONGENITAL GLAUCOMA MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 9. GLOBAL HOSPITALS PHARMACY MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 10. GLOBALRETAIL PHARMACYMARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 11. GLOBAL ONLINE PHARMACYMARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 12. GLOBAL PROSTAGLANDIN ANALOGUES DRUG FOR GLAUCOMA TREATMENT MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 13. GLOBAL ALPHA AGONIST DRUG FOR GLAUCOMA TREATMENTMARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 14. GLOBAL CHOLINERGICDRUG FOR GLAUCOMA TREATMENT MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 15. GLOBAL BETA BLOCKERS DRUG FOR GLAUCOMA TREATMENT MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 16. GLOBAL CARBONIC ANHYDRASE INHIBITORS DRUG FOR GLAUCOMA TREATMENT MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 17. US GLAUCOMA TREATMENT MARKET SIZE, 2020-2027($ MILLION)
  • 18. CANADA GLAUCOMA TREATMENT MARKET SIZE, 2020-2027($ MILLION)
  • 19. UK GLAUCOMA TREATMENT MARKET SIZE, 2020-2027 ($ MILLION)
  • 20. FRANCE GLAUCOMA TREATMENT MARKET SIZE, 2020-2027 ($ MILLION)
  • 21. GERMANY GLAUCOMA TREATMENT MARKET SIZE, 2020-2027 ($ MILLION)
  • 22. ITALY GLAUCOMA TREATMENT MARKET SIZE, 2020-2027 ($ MILLION)
  • 23. SPAIN GLAUCOMA TREATMENT MARKET SIZE, 2020-2027 ($ MILLION)
  • 24. REST OF EUROPE GLAUCOMA TREATMENT MARKET SIZE, 2020-2027 ($ MILLION)
  • 25. INDIA GLAUCOMA TREATMENT MARKET SIZE, 2020-2027 ($ MILLION)
  • 26. CHINA GLAUCOMA TREATMENT MARKET SIZE, 2020-2027 ($ MILLION)
  • 27. JAPAN GLAUCOMA TREATMENT MARKET SIZE, 2020-2027 ($ MILLION)
  • 28. SOUTH KOREA GLAUCOMA TREATMENT MARKET SIZE, 2020-2027 ($ MILLION)
  • 29. REST OF ASIA-PACIFIC GLAUCOMA TREATMENT MARKET SIZE, 2020-2027 ($ MILLION)
  • 30. REST OF THE WORLD GLAUCOMA TREATMENT MARKET SIZE, 2020-2027 ($ MILLION)